Presented by Associate Professor Mick Foley, La Trobe University
Location: Cairns D003-063 videolinked to Townsville 134-102
i-bodies and shark antibodies are single domains with a long CDR3 that permits access to active sites and ligand binding sites on complex proteins such as membrane receptors, GPCRs and ion channels. By screening a large phage library displaying these single domains, high affinity single domain antibodies specific for membrane proteins such as CXCR4 have been obtained. CXCR4 is known to be upregulated in a number of cancers and recently has been implicated in fibrosis. We have shown that the i-bodies are able to block the recruitment of fibrocytes into the lungs of mice with bleomycin induced pulmonary fibrosis and that the anti CXCR4 i-bodies have anti-inflammatory and anti-fibrotic effects in several different animal models. Moreover, we suggest that the i-body technology provides a unique resource for obtaining a toolbox of human antibody single domains to currently intractable membrane proteins. This talk will discuss some of the opportunities and challenges associated with commercialization of basic discoveries.
About Associate Professor Mick Foley
A/Pros Foley has been involved in malaria research at WEHI, the University of Edinburgh, and in the Department of Biochemistry at La Trobe University. He has 25 years’ experience in phage display of antibodies and peptides and has recently been using phage display to identify single domain i-bodies against GPCRs and Ion channels. A/Prof Foley is the founding scientist and CSO of AdAlta and a key inventor of the AdAlta i-body technology, which are libraries of human single domain proteins. AdAlta had an oversubscribed IPO in 2016 and is currently progressing their lead i-body into the clinic for pulmonary fibrosis.